Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres

Abstract

Dupilumab is a monoclonal antibody targeting the interleukin-4 and -13 signalling pathway, and which is proven to be highly effective and safe in atopic dermatitis (AD). Its possible role in treating or inducing cutaneous T-cell lymphomas (CTCLs) has not yet been fully clarified, as several case reports seem to point not only at its beneficial effects but also at a possible pathogenetic role in mycosis fungoides and Sézary syndrome. We present data collected from a cohort of 995 patients with classic or prurigo nodularis-like AD who received dupilumab and were followed longitudinally for a mean period of 25.1 months after first administration to investigate a possible correlation between dupilumab and CTCL development.